Biomarker Discovery Outsourcing Services Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive, Prognostic), By Therapeutic Area (Oncology, Neurology, Autoimmune Diseases), By Phase, By End-use, By Region, And Segment Forecasts, 2023 -

Biomarker Discovery Outsourcing Services Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive, Prognostic), By Therapeutic Area (Oncology, Neurology, Autoimmune Diseases), By Phase, By End-use, By Region, And Segment Forecasts, 2023 - 2030


Biomarker Discovery Outsourcing Services Market Growth & Trends


The global biomarker discovery outsourcing services market size is expected to reach USD 49.32 billion by 2030, growing at a CAGR of 21.1% during the forecast period, according to a new report by Grand View Research, Inc. The expansion of outsourced biomarker research, attributed to the increased utilization of biomarkers in clinical trials and the accelerating level of outsourcing undertaken by pharmaceutical firms are key growth factors for this market.

Furthermore, increasing adoption of liquid biopsies is expected to drive the market growth. Liquid biopsies, which involve the analysis of biomarkers in bodily fluids like blood, urine, and cerebrospinal fluid, offer several advantages over traditional tissue biopsies, such as being less invasive and providing real-time information. As a result, the adoption of liquid biopsies has been growing rapidly, and this trend directly impacts the demand for biomarker discovery outsourcing services.

Advancements in omics technologies are expected to drive market growth in the coming years. Progress in genomics, proteomics, metabolomics, and other omics technologies has enabled the identification of novel biomarkers.Integrating data from many omics disciplines can often be advantageous for biomarker identification. This all-encompassing approach enables a more thorough comprehension of complex disorders and can result in identifying reliable, multidimensional biomarkers.Outsourcing services specializing in multi-omics data integration offer valuable expertise in this area.

An increase in drug development and clinical trials is a major contributing factor to the market growth. Biomarkers play a crucial role in drug development, helping pharmaceutical companies identify suitable drug targets, streamline clinical trial processes, and select patient populations for trials.As of 2023, the global clinical trial landscape boasts 452,604 registered trials on ClinicalTrials.gov, with 64,838 actively enrolling participants. This reflects a notable surge compared to the roughly 365,000 registered trials documented in early 2021, underscoring the robust and ongoing growth within the field of clinical research.

Biomarker Discovery Outsourcing Services Market Report Highlights

  • Based on type, the surrogate endpoints segment held the largest share in 2022. Surrogate biomarkers can provide a more precise understanding of a drug's mechanism of action, allowing for targeted therapies and personalized medicine approaches
  • The predictive biomarkers segment is expected to show significant market share in the coming years. In clinical trials, patient categorization depends on predictive biomarkers
  • In the therapeutic area segment, oncology dominated the market in 2022, accounting for over 34% of the total revenue. The key factors contributing to the growth include the high incidence of cancer, personalized medicine in oncology, and increased drug development in oncology
  • The autoimmune diseases segment is expected to show significant market share in the coming years. This is attributed to the advancements in omics technologies, biomarker-driven drug development, and the introduction of emerging therapies
  • Based on the discovery phase segment, biomarker identification held a major revenue share of over 28% in 2022 due to wide applications of biomarker identifications in drug discovery and development. Pharmaceutical and biotechnology companies heavily rely on biomarker identification to advance their research and development efforts
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.5. Market Driver Analysis
3.6. Market Restraint Analysis
3.7. Business Environment Analysis
3.7.1. SWOT Analysis
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Biomarker Discovery Outsourcing Services Market: Type Movement Analysis
4.2. Predictive biomarkers
4.2.1. Predictive biomarkers Market, 2018 - 2030 (USD Billion)
4.3. Prognostic biomarkers
4.3.1. Prognostic Biomarkers Market, 2018 - 2030 (USD Billion)
4.4. Safety biomarkers
4.4.1. Safety Biomarkers Market, 2018 - 2030 (USD Billion)
4.5. Surrogate endpoints
4.5.1. Surrogate endpoints Market, 2018 - 2030 (USD Billion)
Chapter 5. Therapeutic Area Business Analysis
5.1. Biomarker Discovery Outsourcing Services Market: Therapeutic Area Movement Analysis
5.2. Oncology
5.2.1. Oncology Market, 2018 - 2030 (USD Billion)
5.3. Neurology
5.3.1. Neurology Market, 2018 - 2030 (USD Billion)
5.4. Cardiology
5.4.1. Cardiology Market, 2018 - 2030 (USD Billion)
5.5. Autoimmune Diseases
5.5.1. Autoimmune Diseases Market, 2018 - 2030 (USD Billion)
5.6. Others
5.6.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 6. Discovery Phase Business Analysis
6.1. Biomarker Discovery Outsourcing Services Market: Discovery Phase Movement Analysis
6.2. Biomarker Identification
6.2.1. Biomarker Identification Market, 2018 - 2030 (USD Billion)
6.3. Biomarker Validation
6.3.1. Biomarker Validation Market, 2018 - 2030 (USD Billion)
6.4. Biomarker Profiling
6.4.1. Biomarker Profiling Market, 2018 - 2030 (USD Billion)
6.5. Biomarker Panel Development
6.5.1. Biomarker Panel Development Market, 2018 - 2030 (USD Billion)
6.6. Biomarker Selection
6.6.1. Biomarker Selection Market, 2018 - 2030 (USD Billion)
Chapter 7. End-use end-use Business Analysis
7.1. Biomarker Discovery Outsourcing Services Market: end-use Movement Analysis
7.2. Pharmaceutical Companies
7.2.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Billion)
7.3. Biotechnology Companies
7.3.1. Biotechnology Companies Market, 2018 - 2030 (USD Billion)
7.4. Others
7.4.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 8. Regional Business Analysis
8.1. Biomarker Discovery Outsourcing Services Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. North America Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Regulatory Framework
8.2.2.3. Competitive Scenario
8.2.2.4. U.S. Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Regulatory Framework
8.2.3.3. Competitive Scenario
8.2.3.4. Canada Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.3. Europe
8.3.1. Europe Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.3.2. UK
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. UK Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Germany Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. France Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Italy Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Spain Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.3.7. Sweden
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Sweden Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.3.8. Norway
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Norway Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.3.9. Denmark
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Denmark Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.4. Asia Pacific
8.4.1. Asia Pacific Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Japan Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. China Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. India Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.4.5. Australia
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Australia Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. South Korea Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Thailand Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.5. Latin America
8.5.1. Latin America Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Brazil Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Mexico Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Argentina Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.6. MEA
8.6.1. MEA Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. South Africa Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Saudi Arabia Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. UAE Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Kuwait Biomarker Discovery Outsourcing Services Market, 2018 - 2030 (USD Billion)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.2.1. Merger& Acquisition
9.2.2. Collaborations
9.2.3. New Product Launch
9.3. Participant’s overview
9.3.1. Laboratory Corporation of America Holdings
9.3.1.1. Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Charles River Laboratories
9.3.2.1. Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Eurofins Scientific
9.3.3.1. Overview
9.3.3.2. Financial Performance
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Celerion
9.3.4.1. Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. ICON plc
9.3.5.1. Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Parexel International (MA) Corporation
9.3.6.1. Overview
9.3.6.2. Financial Performance
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Proteome Sciences
9.3.7.1. Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. GHO Capital
9.3.8.1. Overview
9.3.8.2. Financial Performance
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Thermo Fisher Scientific Inc
9.3.9.1. Overview
9.3.9.2. Financial Performance
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Evotec
9.3.10.1. Overview
9.3.10.2. Financial Performance
9.3.10.3. Product Benchmarking
9.3.10.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings